Biotron updates on BIT225-012 Phase 2 COVID-19 clinical trial - Biotech Dispatch
Biotron's BIT225-012 Phase 2 trial met safety and tolerability endpoints but failed to meet primary efficacy endpoint in reducing SARS-CoV-2 nasal viral load. Four participants had unquantifiable nasal virus levels on Day 1. Biotron remains optimistic about its viroporin antagonist platform.
Reference News
Biotron updates on BIT225-012 Phase 2 COVID-19 clinical trial - Biotech Dispatch
Biotron's BIT225-012 Phase 2 trial met safety and tolerability endpoints but failed to meet primary efficacy endpoint in reducing SARS-CoV-2 nasal viral load. Four participants had unquantifiable nasal virus levels on Day 1. Biotron remains optimistic about its viroporin antagonist platform.